Reynolds SR - Search Results

1

Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.

Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC. Reynolds SR, et al. Clin Cancer Res. 2003 Feb;9(2):657-62. Clin Cancer Res. 2003. PMID: 12576432

2

Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma.

Reynolds SR, Albrecht J, Shapiro RL, Roses DF, Harris MN, Conrad A, Zeleniuch-Jacquotte A, Bystryn JC. Reynolds SR, et al. Clin Cancer Res. 2003 Apr;9(4):1497-502. Clin Cancer Res. 2003. PMID: 12684425

3

Melanoma vaccines: what we know so far.

Bystryn JC, Reynolds SR. Bystryn JC, et al. Among authors: reynolds sr. Oncology (Williston Park). 2005 Jan;19(1):97-108; discussion 108, 111-2, 115. Oncology (Williston Park). 2005. PMID: 15743154 Free article. Review.

4

Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy?

Reynolds SR, Vergilis IJ, Szarek M, Ferrone S, Bystryn JC. Reynolds SR, et al. Int J Cancer. 2006 Jul 1;119(1):157-61. doi: 10.1002/ijc.21820. Int J Cancer. 2006. PMID: 16450373 Clinical Trial.

5

Identification of melanoma antigens that are immunogenic in humans and expressed in vivo.

Applebaum J, Reynolds S, Knispel J, Oratz R, Shapiro R, Bystryn JC. Applebaum J, et al. J Natl Cancer Inst. 1998 Jan 21;90(2):146-9. doi: 10.1093/jnci/90.2.146. J Natl Cancer Inst. 1998. PMID: 9450575

6

Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.

Reynolds SR, Oratz R, Shapiro RL, Hao P, Yun Z, Fotino M, Vukmanović S, Bystryn JC. Reynolds SR, et al. Int J Cancer. 1997 Sep 17;72(6):972-6. doi: 10.1002/(sici)1097-0215(19970917)72:6<972::aid-ijc9>3.0.co;2-m. Int J Cancer. 1997. PMID: 9378560 Clinical Trial.

7

HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.

Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC. Reynolds SR, et al. J Immunol. 1998 Dec 15;161(12):6970-6. J Immunol. 1998. PMID: 9862732

8

Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.

Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC. Reynolds SR, et al. J Immunol Methods. 2000 Oct 20;244(1-2):59-67. doi: 10.1016/s0022-1759(00)00254-4. J Immunol Methods. 2000. PMID: 11033019 Free article.

9

Decrease in circulating tumor cells as an early marker of therapy effectiveness.

Bystryn JC, Albrecht J, Reynolds SR, Rivas MC, Oratz R, Shapiro RL, Roses DF, Harris MN, Conrad A. Bystryn JC, et al. Among authors: reynolds sr. Recent Results Cancer Res. 2001;158:204-7. doi: 10.1007/978-3-642-59537-0_21. Recent Results Cancer Res. 2001. PMID: 11092048

10

Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice.

Johnston D, Reynolds SR, Bystryn JC. Johnston D, et al. Among authors: reynolds sr. Cancer Immunol Immunother. 2006 Apr;55(4):412-9. doi: 10.1007/s00262-005-0013-x. Epub 2005 Sep 6. Cancer Immunol Immunother. 2006. PMID: 16151809 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Search Page

Filters